Loading…
Asston Pharmaceuticals (BSE 544445)₹151.25+7.19%Pharmaceuticals
At the end of the Mar 2026 quarter, Asston Pharmaceuticals' shareholders were: promoters 50.65%, FIIs 1.90%, public 47.45%. Promoter holding is unchanged on the quarter. 0.00% of promoter shares were pledged. It had 688 shareholders.
As of · Company filings (shareholding pattern)
| Sep 2025 | Mar 2026 | |
|---|---|---|
| Promoters | 50.65% | 50.65% |
| FIIs | 6.03% | 1.90% |
| Public | 43.32% | 47.45% |
| Promoter shares pledged | — | 0.00% |
| Number of shareholders | 752 | 688 |
| Holder | Category | Mar 2026 | Change (pp) |
|---|---|---|---|
| Ashish Narayan Sakalkar | Promoter | 21.79% | — |
| Saili Jayaram More | Promoter | 21.78% | — |
| Sachin Chandrakant Badakh | Promoter | 7.19% | — |
| Mahesh Vishnupant Mulay | Public | 2.92% | — |
| Kuldip Singh Rathee | Public | 2.36% | — |
| Minerva Ventures Fund | FII | 1.92% | — |
| Vrushali Yogesh Supekar | Public | 1.47% | — |
| Dilip Rameshchandra Jagad | Public | 1.24% | — |
Promoters held 50.65% of Asston Pharmaceuticals at the end of the Mar 2026 quarter.
In the Mar 2026 quarter, foreign institutional investors (FIIs) held 1.90% (down 4.13 percentage points from 6.03% a quarter earlier) and domestic institutions (DIIs) held no reported stake.
No. The Mar 2026 filing shows no pledged promoter shares.
Asston Pharmaceuticals had 688 shareholders at the end of the Mar 2026 quarter.
Mahesh Vishnupant Mulay (Public) held 2.92% at the end of the Mar 2026 quarter, the largest named holding outside the promoter group.